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A B S T R A C T
Aims: High plantar pressure is a major risk factor in the development of diabetic foot ulcers
(DFUs) and recent evidence shows plantar pressure feedback reduces DFU recurrence. This
study investigated whether continued use of an intelligent insole system by patients at
high-risk of DFUs causes a reduction in plantar pressures.
Methods: Forty-six patients with diabetic peripheral neuropathy and previous DFU were
randomised to intervention (IG) or control groups (CG). Patients received an intelligent
insole system, consisting of pressure-sensing insoles and digital watch. Patients wore
the device during all daily activity for 18-months or until ulceration, and integrated pres-
sure was recorded continuously. The device provided high-pressure feedback to IG only
via audio-visual-vibrational alerts. High-pressure parameters at the whole foot, forefoot
and rearfoot were compared between groups, with multilevel binary logistic regression
analysis.
Results: CG experienced more high-pressure bouts over time than IG across all areas of the
foot (P < 0.05). Differences between groups became apparent >16 weeks of wearing the
device.
Conclusions: Continuous plantar pressure feedback via an intelligent insole system reduces
number of bouts of high-pressure in patients at high-risk of DFU. These findings suggest
that patients were learning which activities generated high-pressure, and pre-emptively
offloading to avoid further alerts.
 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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0168-8227/ 2021 The Authors. Published by Elsevier B.V.
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There is consensus across the literature on the key role of
high plantar pressures in the development of diabetic foot
ulcers (DFUs). High plantar pressure on the diabetic foot is
the result of a multitude of risk factors, including diabetic
peripheral neuropathy (DPN) and foot deformities[1–3]. DPN
results in a loss of protective sensation and is the predomi-
nant risk factor for DFU development as it limits the ability
for self-regulation of foot pressures.
TheprimaryaimofDFUprevention strategies is to reducehigh
plantar pressures. Current prevention strategies, centred around
prescription footwearandorthotics, are onlyeffectivewhenworn,
however are often associatedwith low adherence[4–8].
Providing personalised feedback on high plantar pressures
offersanalternativestrategy for thepatient to reduce theirplan-
tarpressures,with thepotential fora learningeffect over time.A
smallnumberof laboratory-basedstudieshave investigated this
concept,with themajority providingvisual feedback for a single
‘at-risk’ area of peak pressure, identified following a walking
trial[9–11]. Studieshaveshownthat a single laboratoryvisitwith
this feedback significantly reduced pressure to the at-risk area,
with the effects lasting for up to 10 days[10,11]. However, no
longer-term reductions to plantar pressure were reported in
high-risk patients following two feedback sessions, suggesting
the need formore frequent pressure feedback to achievemean-
ingful reductions towards DFU prevention[9].
A few biofeedback studies have also monitored pressure
across all areas of the foot[9,11,12]. This is particularly relevant
considering that after successful offloading of an at-risk area, a
significant increase in plantar pressure to the contralateral
mid-footwas identified in one study[11]. These studies, however,
were small-scale and laboratory-based, and further investigation
through a randomised control trial of a continuous monitoring
system over a sustained follow-up period is required.
Advancements in intelligent technologies have seen the
development of pressure-feedback systems that are able to
continuously analyse and provide feedback to the patient
[13,14]. The development of such intelligent systems in DFU
prevention, however, is an emerging area.
The aim of the current study was to investigate whether
daily use of an intelligent insole system, providing continu-
ous, personalised high-pressure feedback, can reduce pres-
sure to the at-risk diabetic foot over an 18-month period.
The current study was part of a randomised controlled trial
of an intelligent insole system for reducing DFU in high-risk
patients, for which we have recently reported efficacy[15].
We hypothesise that DFU prevention seen in the previous
study, was due to reduced plantar pressure resulting from
pressure feedback. Although the current study involves the
same patient cohort as in our previously published study of
DFU incidence, this represents a separate aspect and, in con-
trast, examines a new dataset of novel plantar pressure data.
2. Materials and methods
2.1. Subjects
Patients were recruited from two hospital sites in the UK. Eli-
gibility criteria have been previously described in detail by
Abbott [15]. Inclusion criteria included: Type 1 or Type 2 dia-
betes; DPN; age > 18 years; previous DFU on the weight-
bearing surfaces of the foot. Exclusion criteria included:
active DFU; severe vascular disease; Body Mass
Index > 40 kg/m2. Patients provided written consent in accor-
dance with study procedures approved by local research
ethics committees and governance bodies in the UK (clinical
trial registration number: ISRCTN05585501; NHS REC refer-
ence number: 13/NW/0649).
2.2. Study design
In this prospective, randomised controlled trial, all recruited
patients were required to undergo initial screening to confirm
eligibility. Presence and severity of DPN were assessed with
the modified neuropathy disability score; testing pain, vibra-
tion and temperature sensation, and ankle reflexes, with
any loss of sensation classified as DPN[16,17]. Additional
assessments included: cutaneous pressure perception at the
great toe, first, third and fifth metatarsal heads, using a 10 g
monofilament; vibration perception threshold at the great
toe using a Biothesiometer (Medical Instruments, Newbury,
OH, USA); the NeuropadTM test (Trigocare, Wiehl, Germany)
identifying presence of sudomotor dysfunction.
Following a successful screening visit, patients were ran-
domised using a single-blinded design to the Intervention
Group (IG) or Control Group (CG). Patients were monitored
on a monthly basis for 18-months, or until a plantar DFU
developed. All patients continued with their standard podia-
try and diabetes-related foot care throughout the study.
At each monthly visit, a foot examination took place to
identify any new plantar DFUs or any areas that appeared to
be at risk of ulceration[18].
2.3. Intelligent insole system
All recruited patients were providedwith their own intelligent
insole system (SurroSense Rx, Orpyx Medical Technologies
Inc., Calgary, AB, Canada), which consisted of a pair of
pressure-sensing 0.6 mm flexible insoles and a digital display
watch, all of which were worn for the duration of the study,
throughout daily life (Fig. 1.A). Only patients in the IG had
an intelligent system that provided feedback on their foot
pressures via their watch; the CG did not receive any feed-
back. Patients were required to select a pair of shoes for insole
placement, which were worn for most daily life activities;
shoes ranged from off-the-shelf to custom-made. Only
researchers were permitted to remove and fit the pressure-
sensing insoles to ensure proper placement and prevent dam-
age. The pressure-sensing insoles were placed underneath
patient’s own orthotics/insoles; in rare cases where patients
did not have their own, a standard, non-customised insole
(3 mm Poron) was provided. Pressure-sensing insole calibra-
tion took place at device set-up and each monthly visit; this
accounted for the low pressure exerted by the patient’s own
insole covering the pressure-sensing insole.
Plantar pressure was collected from the intelligent insoles
at a sampling rate of 8 Hz from eight sensors located on the
plantar surface (Fig. 1.B). Pressure data were analysed and
categorised by the device as being either above or below
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plantar tissue capillary perfusion pressure (35 mmHg)[19]. For
each sensor, the insole system integrated pressure data col-
lected over the previous 15 min into ‘high’, ‘medium’ or
‘low’ categories based on the percentage of data which
exceeded capillary pressure (‘high’ = 95–100%
readings  35 mmHg, ‘medium’ = 35–94% 35 mmHg,
‘low’ = 0–34% 35 mmHg). Categorisation was completed
every minute of wear and was wirelessly transmitted to the
digital watch where data was stored.
Following screening, all recruited patients began with a
two-week familiarisation period, which involved wearing
the insole system with a non-alerting (no pressure-
feedback) watch. Following familiarisation, the IG had their



































Fig. 1 – Intelligent insole system (SurroSense Rx, Orpyx Medical Technologies, Alberta, Canada). (A) Intelligent insole system
including digital display watch and pressure-sensing insoles worn in patients’ own shoes, only Velcro or laced shoes were
permitted to ensure secure attachment of the sensor pod to the shoe exterior. NB figure does not show patient’s own insoles
that were required to be worn on top of the pressure-sensing insoles. (B) Locations of the eight sensor sites on the pressure-
sensing insole, indicating forefoot and rearfoot. Numbers indicate which of the four foot-map areas each sensor corresponds
to. (C) Digital watch display showing the foot map where areas of sustained high pressure were highlighted in red for IG only.
(D) Visual representation of bouts of high pressure. For every new bout of high pressure, the IG received an alert on the
smartwatch in addition to standard off-loading guidance, which encouraged patients to 1) walk around for 2 min; if the alert
was not removed then: 2) actively off-load the affected foot by sitting down, if still not effective: 3) check for over-tightness of
the shoe and any foreign bodies.
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new bout of sustained high pressure was detected at any sen-
sor site, the watch (IG only) provided a vibrational and audio-
visual alert, highlighting areas of high pressure in red on the
watch display’s ‘foot-map’ (Fig. 1.C), in addition to standard
off-loading guidance. The watch provided reminder alerts
until successful offloading occurred, clearing the alert. The
watch display’s foot-map separated the plantar surface into
four areas; however, raw data was specific to each of the eight
sensors.
All patients in IG and CG wore the same intelligent insole
system, which recorded plantar pressure data throughout
daily life when shoes were worn. Patients were encouraged
to wear the insole system as often as possible throughout
the follow-up, with adherence monitored at each monthly
visit. The important difference between the groups was that
only the IG received pressure feedback; in contrast, the CG
had a device that did NOT provide any pressure feedback.
2.4. Data analysis
A reading of ‘high’ (95–100% 35 mmHg), ‘medium’ or ‘low’
integrated pressurewas recorded for each of the eight sensors
on each insole, every minute of wear, for the duration of the
follow-up period (18 months). Occurrences of sustained high
pressure were the primary focus of this study. Due to the large
volume of data, custom scripts were developed in MATLAB to
enable data processing. Pressure data were analysed for each
patient-foot independently, rather than combining left and
right feet. High plantar pressure is a precursor for DFU devel-
opment and DFUs do not always develop on both feet, but
when they do, the locations of such are not often identical
for both feet, highlighting the independence of these events.
Therefore, this provides evidence to suggest that plantar pres-
sures not only differ across the foot, but also between feet.
Furthermore, IG patients within this study received pressure
feedback that was independent to each foot and so authors
treated them as such. A similar approach was adopted in pre-
vious studies[20,21].
The following parameters were derived for each sensor:
number of bouts of sustained high pressure (where a bout
was a group of continuous high pressure readings, for each
new bout, IG received an alert (Fig. 1.D)), minutes of sustained
high pressure, bout duration of sustained high pressure (the
length of time sustained pressure readings persisted). All
parameters were normalised per hours of wear. Averages over
4-week periods were calculated for each individual sensor.
Whole foot totals were calculated using the sum of all eight
sensors. The forefoot region was defined as the five sensors
covering the toes and metatarsal head regions, whereas the
rearfoot covered the remaining three sensors (Fig. 1.B). Four-
week periods were specific to each patient-foot and the
patient’s study start date due to the staggered nature of
patient recruitment. Four-weekly periods that contained zero
pressure data for both patient’s feet were removed.
Low compliance was assessed by calculating the time in
study (hours) from the number of days each patient was
enrolled onto the study, divided by total hours the device
was worn. Distribution of results was plotted via scatter and
boxplots to identify negative outliers as low compliers, which
were subsequently removed from further analyses.
2.5. Statistical analysis
Baseline patient demographics and other study outcomes
were compared between treatment groups. Variables were
compared with an Independent Student’s t-test, Mann-
Whitney U test, or Chi-squared (X2) test of independence
where appropriate.
Multilevel binary logistic regression was performed to
investigate the effect of the intervention on pressure variables
over the study period, accounting for months with missing
data and patients withdrawing. For each parameter, two mul-
tilevel models were performed, both included using group
and month as fixed effects; the IG was the reference group.
In addition, one model included the nested interaction term
‘group*month’ to investigate whether the change in pressure
variables over the study period differed between IG and CG.
As described, analysis was grouped by individual feet. All
analyses were run using SPSS version 25 (IBM Corporation,
Armonk, NY) with a significance level of P < 0.05 and 95% CI.
3. Results
Fifty-eight people were randomised to the study, as previously
described[15]. Four patients’devices did not provide sufficient
pressure data during their time in study and these patients
were subsequently excluded from pressure analyses. Follow-
ing analysis of hours of wear data, an additional eight
patients were identified as low compliers and were also
removed from analyses.
The baseline patient demographics of the remaining
patients (n = 46) are summarised in Table 1. The IG was signif-
icantly younger (59.5 ± 9.1 vs 66.4 ± 9.1 years, P = 0.014); how-
ever, all other characteristics were similar between IG and CG.
The average follow-up period was 12.0 ± 6.8 months and
did not differ between groups (median 12(1–22) months CG,
13(1–22) months IG P = 0.479). Twenty-five patients did not
complete the full study follow-up due to development of a
plantar DFU (n = 10), loss of contact (n = 1) and withdrawal
before completion (n = 14); however, such patients’ pressure
data was included in the analyses as it fit within the study
objectives and ethical permissions.
3.1. High pressure results
The number of 4-week periods for which pressure data was
available did not differ between groups (median 13(1–23) 4-
weeks CG, 12(2–24) 4-weeks IG P = 0.635). The average hours
the intelligent insole system was worn per day, was also sim-
ilar between groups (6.78 ± 2.2 h CG, 6.01 ± 2.02 h IG P = 0.192).
The results of the sustained high-pressure parameters: num-
ber of bouts and minutes, for individual feet (n = 92) are pre-
sented below and in Figs. 2 and 3, respectively. Results for
bout duration of pressure failed to reach significance and
were highly variable.
3.1.1. Bouts of pressure
On average, holding time in study (weeks) constant, the CG
experienced 0.08(95% CI, 0.40 to 0.57, P = 0.73) more bouts
of high-pressure per hour than the IG for the whole foot,
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although this did not reach significance (Fig. 2). The number
of bouts of high pressure at the forefoot and rearfoot also
showed no significant differences between groups when time
in study was held constant. However, the interaction effect of
group and time in study showed the number of bouts of high
pressure were significantly greater over time for the CG com-
pared to the IG for whole foot ‘0.053(0.018 to 0.088, P = 0.003)’,
forefoot ‘0.022(0.0002 to 0.044, P = 0.048)’, and rearfoot ‘0.029
(0.011 to 0.047, P = 0.001)’.
3.1.2. Minutes of pressure
On average, holding time in study (weeks) constant, the CG
experienced 6.9(-7.4 to 21, P = 0.34) more minutes of high
pressure per hour than the IG for the whole foot (Fig. 3). In
addition, on average, more minutes of high pressure per hour
were evident in the CG when separating the foot into forefoot
‘3.5(-6.9 to 14.0, P = 0.51)’ and rearfoot ‘3.5(-2.7 to 9.6, P = 0.26)’.
However, such differences did not reach significance. Further-
more, the interaction effect of group and time in study indi-
cated that over time, minutes of high pressure per hour
remained higher for the CG compared to IG, however such
result was non-significant (whole foot ‘0.6(-0.56 to 1.8,
P = 0.31)’, forefoot ‘0.12(-0.69 to 0.93, P = 0.77)’, rearfoot ‘0.47
(-0.11 to 1.1, P = 0.11)’).
4. Discussion
For the first time, we have shown that providing continuous,
high-pressure, personalised feedback during daily activities
over a prolonged time-period, has reduced plantar pressure
in patients at high-risk of DFU. Importantly, IG patients dis-
played a learning response following approximately four
months of receiving pressure-feedback.





Male 18 (86%) 23 (92%)
Age (years)* 66.4 (9.13) 59.5 (9.07)
BMI (kg/m2) 31.5 (4.74) 31.8 (5.73)
Type 2 diabetes 18 (86%) 17 (68%)













































Previous amputations, left foot
None
Great toe







Previous amputations, right foot
None
Great toe















Data are mean (SD), n (%) or median (range). Study site 1 = Manchester. NDS = Neuropathy Disability Score, scored out of 10 with 10 being most
severe. An abnormal 10 g monofilament result was defined as the inability to detect the 10 g monofilament at any one of the tested plantar sites
(great toe, first, third and fifth metatarsal head). Foot deformity score, scored from 0 to 6, a score of 1 for each of the following deformities
identified per foot: hammer or claw toes, prominent metatarsal heads, small muscle wasting, bony prominences, Charcot, or limited joint
ability as determined by prayer sign. *Significantly different (P < 0.05) between control (CG) and intervention (IG). †CG n = 20, IG n = 22. CG
n = 20, IG n = 25. §CG n = 19, IG n = 20. –CG n = 18, IG n = 23.
























































































Fig. 2 – Average number of bouts of sustained high pressure
per hour of wear at the (A) Whole foot, (B) Forefoot and (C)
Rearfoot regions, comparing IG to CG. Averages were
calculated for every 4-week period worn, see results for 95%
CI as an indication of variation. *The interaction effect of
group and time in study (weeks) was significantly greater for
the CG (P < 0.05). Due to withdrawals and in-study DFUs
throughout the follow-up period, the number of patients
reduced over time, the number of feet every third 4-week
period for figures A, B and C were as follows: weeks 9–12
n = 84 (36 CG, 48 IG); weeks 21–24 n = 74 (32 CG, 42 IG), weeks
33–36 n = 60 (26 CG, 34 IG); weeks 45–48 n = 52 (22 CG, 30 IG);


































































































Fig. 3 – Average minutes of sustained high pressure per
hour of wear at the (A) Whole foot, (B) Forefoot sensors and
(C) Rearfoot sensors, comparing the IG, who were alerted
when in a high-pressure state, to the CGwho did not receive
any pressure-feedback. Averages were calculated every
4 weeks, see results for 95% CI as an indication of variation.
N.B For each region, the sum of the corresponding sensors
was used; therefore, it is possible for a total reading above
60 min/hour, as all sensors could in theory read high
pressure at the same time. Due to withdrawals and in-study
DFUs throughout the follow-up period, the number of
patients reduced over time, the number of feet every third 4-
week period were as follows: weeks 9–12 n = 84 (36 CG, 48
IG);weeks 21–24 n = 74 (32 CG, 42 IG), weeks 33–36 n = 60 (26
CG, 34 IG); weeks 45–48 n = 52 (22 CG, 30 IG); weeks 57–60
n = 36 (18 CG, 18 IG); weeks 69–72 n = 34 (16 CG, 18 IG).
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When analysing the whole foot (Fig. 3), the number of
bouts of sustained high pressure (group of continuous high-
pressure readings, alerting the IG) were similar for IG and
CG during the first 16 weeks of the study. However, after
16 weeks of wearing the intelligent insole system, the number
of bouts of high-pressure became significantly lower for the
IG compared to CG and remained lower for the duration of
the study. This suggests a learning response in the IG, where
during the first 16 weeks of receiving continuous high-
pressure feedback, the IG began to learn which activities/foot
positions resulted in high-pressure alerts and were able to
pre-empt and largely avoid these bouts of high pressure from
this point and for the remaining duration of the study. Similar
results were recorded when the forefoot and rearfoot pres-
sures were examined separately. The forefoot, where most
DFUs occur[22], had a shorter learning response, with the
number of bouts remaining lower for the IG following just
12 weeks of wear, whereas the rearfoot, showed a positive
learning response following 20 weeks of receiving pressure-
feedback.
Events triggering high-pressure alerts were likely to have
been specific to each individual. However, commonly
patient-reported events included; driving or standing still for
prolonged periods, sitting down with feet in a fixed position
e.g. tucked under a chair, with actually very few reports of
alerts during walking[15]. Despite the significantly reduced
bouts of high-pressure in the IG, from week to week the num-
ber of high-pressure bouts fluctuated and did not necessarily
show a continual decrease over time (Fig. 2). Nevertheless,
the average number of high-pressure bouts for the whole foot
reached its peak at the 12th week whilst IG patients were still
‘learning’ from feedback, and although results did fluctuate,
the average number of bouts remained below this level for
the duration of the follow-up. In contrast, the CG recorded
the highest number of bouts at the final 4-week period (week
76), indicating a different pattern where plantar pressures
continued to rise in the absence of any intervention. The fluc-
tuations in the data evident in both groups are highly likely to
be the result of recording such large volumes of pressure con-
tinuously over a very long period, duringwhich patient’s activ-
ity levels and pressure would be expected to vary, in addition
to the gradual decline in the number of patients remaining
in the study. However, despite the variation, a positive effect
from receiving high-pressure feedback is still evident when
looking at changes over the 18-month follow-up period.
Although the CG generally experienced more high pres-
sure for all parameters, the bout duration and number of min-
utes of high pressure failed to yield any significant differences
and results again did fluctuate. Nevertheless, any small differ-
ences should be considered potentially important as they
have the potential to accumulate to larger differences over
time, which could be clinically meaningful in terms of DFU
prevention. As the intelligent insole system used in the cur-
rent study involves a unique method of measuring pressure
continuously, it is unknown how much of a reduction in high
pressure could result in a positive DFU prevention response.
This trial has recently reported a 71% reduction in DFU inci-
dence to the IG, therefore this present study provides evi-
dence of the underpinning mechanism enabling the
reduction in DFU occurrence, which we suggest relates to a
reduction in plantar pressure, specifically the number of
high-pressure bouts[15].
The current study is unique compared to previous
laboratory-based studies providing pressure feedback to
patients with diabetes, as feedback here was provided contin-
uously throughout daily activities over a prolonged period
(18 months). Previous research has provided visual pressure-
feedback on walking only, following standardised trials inside
a laboratory, mostly on a single occasion[10,11]. Such condi-
tions are more controllable and therefore more likely to pro-
duce less variable results with perhaps more notable
differences; however, it is not fully clear how applicable such
results are to plantar pressure experienced throughout daily
life. Whilst significant reductions in plantar pressure were
reported in studies with relatively low-risk diabetes patients
using pressure-feedback, no significant reductions were
reported in a high-risk cohort[9]. These findings suggest con-
tinuous, personalised feedback may be favourable for dia-
betes patients at a higher risk of DFU, such as those
included in the present study. Furthermore, previous studies
identified a single at-risk area and provided feedback specific
to that area only. As identified in previous literature, focusing
on only one at-risk area has the potential to overlook the
development of other at-risk areas due to a shift in pressure
distribution[9,11,12]. However, if such studies were to provide
feedback on more than one at-risk area, this would have per-
haps overloaded the patients due to the feedback methodol-
ogy used. The intelligent insole system used in this study
allows the patient to continually receive feedback from eight
sensors positioned across the whole plantar surface of the
foot, via the watch display’s foot-map and audio-vibrational
alerts (Fig. 1). The nature of the feedback provided is arguably
easier and quicker to process than looking at a target range on
a figure on a computer screen, therefore prevents patients
from being overloaded with information. Furthermore, the
device used in this study, measures plantar pressure and pro-
vides high-pressure feedback throughout all daily activities;
therefore, it has the potential to reduce accumulated plantar
pressures in activities such as standing and sitting as well as
walking, potentially preventing more DFUs, than feedback
provided on walking alone. To the authors’ knowledge, no
previous research exists measuring plantar pressure of
patients with diabetes whilst completing other daily activi-
ties, with previous laboratory-based studies limited to
walking.
The insole system used in this study had a 8 Hz sampling
rate, considerably lower than pressure analysis in previous
studies, where the minimum rate is often 50 Hz[9,11]. How-
ever, rather than this being a limitation, 8 Hz is believed to
be adequate for recording an accumulation of high plantar
pressure over time, in addition to being a compromise for
the amount of data stored over the prolonged period. Unlike
the present study, most studies measuring diabetic plantar
pressure analyse peak pressure. Although the difference in
pressure parameters limits how much we can compare the
current study’s findings to previous results, an accumulation
of high, but not peak pressure, represents a risk for DFU
development[19].
The current study was limited by high withdrawal rates
both pre- and post-randomisation. However, due to the
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nature of the study we were able to include data from with-
drawals post-randomisation in the analysis up until the point
of withdrawal. In addition, the follow-up period was similar
for IG and CG and statistical analyses were not affected by a
continual reduction in patient numbers over the follow-up;
nevertheless, this likely contributed to high variation within
the data. Anecdotal reports indicated possible reasons for
withdrawal included difficulty in using the touchscreen and
intelligent technology. In addition, the high-risk nature of
the patients meant that many had comorbidities and so par-
ticipation in this study for some meant too many appoint-
ments, resulting in withdrawal. Further reasons for
withdrawal included reluctance to wearing only laced or Vel-
cro shoes and custom-made footwear not being suitable for
intelligent insole placement. Future updates to the insole sys-
tem, or new interventions, can utilise this anecdotal feedback
on withdrawals to improve adherence.
The current study was part of a randomised controlled
trial with the primary outcome being DFU incidence.
Therefore, the study sample size calculation was primarily
designed to investigate differences in ulcer incidence
between groups, rather than plantar pressure changes,
which carries the risk of the present study being under-
powered. However, due to the lack of previous research
assessing plantar pressure in the same way as the current
study and over such a long follow-up period, there was no
available comparable data and an accurate sample size cal-
culation was therefore difficult to determine. Although
some plantar pressure parameters were non-significant
and could have been under-powered, there was a signifi-
cant difference for the interaction effect of the number of
bouts of high pressure, indicating adequate statistical
power for this parameter.
Despite randomisation to groups, the IG was significantly
younger than the CG, however, it is unlikely this has influ-
enced the differences in plantar pressure shown between
groups. There is little evidence for the effect of age per se on
plantar pressures in diabetes, therefore, it is unlikely that
the younger age of IG contributed to fewer high-pressure
bouts recorded over time. Plantar pressure for this cohort is
more likely to have been influenced by factors such as BMI,
ulcer history, foot deformity, DPN and duration of diabetes
for which IG and CG were similar.
In summary, continuous pressure feedback over 18-
months via an intelligent insole system reduced high plantar
pressure in high-risk diabetes patients, by inducing a learning
response. The learning response was identified as early as the
12th week of wear, with the positive reduction in pressure
remaining for the duration of the 18-month study. This
unique insole system was able to provide feedback through-
out daily activities (not confined to laboratory) and the resul-
tant pressure reduction is assumed to be the mechanism for
reduced DFU incidence.
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